← Eichor
Condition: Measurable Residual Disease Mrd Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Measurable Residual Disease Mrd

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequenti
Phase 2 · 11 location(s) · SCRI Development Innovations, LLC · NCT06974786ctDNA Analysis to Monitor the Risk of Progression After First-line Immunotherapy in Patients With Advanced NSCLC
Phase N/A · 1 location(s) · Fang Wu · NCT05198154Molecular Residual Disease Assessment in a Representative Diverse Population of Patients With Early-stage Breast Cancer
NA · 1 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT07025785European Project for ctDNA Detection as a Biomarker for Non-invasive Therapy Monitoring in Paediatric Classical Hodgkin
Phase N/A · 1 location(s) · Assistance Publique - Hôpitaux de Paris · NCT07356882GUIDE.MRD-01-CRC: Clinical Validation and Benchmarking of Top Performing ctDNA Diagnostics - Colorectal Cancer
Phase N/A · 15 location(s) · Claus Lindbjerg Andersen · NCT06111105Clinical Research of Drug Holiday Based on MRD Detection in GIST Patients at High Risk of Recurrence
Phase N/A · 1 location(s) · Peking University People's Hospital · NCT05867901To Conduct Multi-omics Integrated Studies in Peripheral Blood, Such as Fragment Omics, Metabolomics and Epigenetics, and
Phase N/A · 1 location(s) · Peking University People's Hospital · NCT07291921CD19 CAR-T vs DLI for Post-HSCT MRD in Ph- ALL: A RCT
Phase 3 · 1 location(s) · Peking University People's Hospital · NCT07441291MRD-Guided Consolidation Therapy Following Definitive Radiotherapy in Esophageal Cancer
Phase 2 · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT06498752Chidamide Maintenance for MRD-Positive Double-Expressor DLBCL in First Complete Remission
Phase 2 · 1 location(s) · Rong Tao · NCT07507318French Assessment of MRD by Liquid Biopsies in Colorectal With Liver Metastasis Patients (FRENCH.MRD.CRLM)
Phase N/A · 2 location(s) · University Hospital, Montpellier · NCT06287723Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia
Phase 2 · 14 location(s) · Grupo Cooperativo de Estudio y Tratamiento de las Leucemias · NCT06668558Comparison Between Local Radiotherapy Alone or Combined With Obinutuzumab in Early Stage Follicular Lymphoma: the GAZEBO
Phase 3 · 49 location(s) · Fondazione Italiana Linfomi - ETS · NCT05929222Use of a New Medicine "Daratumumab" to Treat Left-over Cancer in a Blood Cancer Called "T Acute Lymphoblastic Leukemia"
Phase 2 · 1 location(s) · Tata Memorial Centre · NCT07021677Free From Maintenance Drug Therapy in Multiple Myeloma (The FREEDMM Trial) for Minimal Residual Disease (MRD
Phase 1 · 1 location(s) · University of Illinois at Chicago · NCT05192122Platform Study of Circulating Tumor DNA Directed Adjuvant Chemotherapy in Colon Cancer (KCSG CO22-12)
Phase 3 · 3 location(s) · Seoul National University Hospital · NCT05534087Discontinuation Study
NA · 1 location(s) · University College Cork · NCT05866757MRD-Directed Consolidation With Epcor-only or Epcor-R2 Post Anti-CD19 CAR TCell Therapy for Large B-Cell Lymphoma
Phase 2 · 6 location(s) · Peter MacCallum Cancer Centre, Australia · NCT06414148Phase Ib Study of CD33 FPBMC in Patients With MRD+ AML or MDS
Phase 1 · 1 location(s) · University of Virginia · NCT07270978Feasibility and Safety of Donor-derived NK-cell Infusions for Leukemia Relapse Prophylaxis After Hematopoietic Stem Cell
Phase 2 · 1 location(s) · Federal Research Institute of Pediatric Hematology, Oncology · NCT07256210Infusion of Alloreactive nk Cells for Mrd-positive Aml Patients
NA · 1 location(s) · IRCCS Azienda Ospedaliero-Universitaria di Bologna · NCT06885476MRD Response-adapted Allo-HSCT for Adverse-risk AML
NA · 1 location(s) · Peking University People's Hospital · NCT06301425Asian Multicenter Prospective Study in HER2 Positive Early Breast Cancer for Detecting MRD by ctDNA;HARMONY Study
Phase N/A · 1 location(s) · National Cancer Center, Japan · NCT05433753Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection
Phase 4 · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT06409702Evaluating the Uptake and Utility of Clinical Pathways for Newly Diagnosed Patients With Multiple Myeloma
Phase N/A · 1 location(s) · All4Cure · NCT06149910A Study of Chidamide With AZA in MRD Positive AML After Transplant
NA · 1 location(s) · Guangdong Provincial People's Hospital · NCT06066905Digital PCR of CHIP and MR for MRD Monitoring After Allo-HSCT in AML
Phase N/A · 1 location(s) · Peking University People's Hospital · NCT07500441Efficacy of Short-course Blinatumomab for MRD Erradication in B-ALL
Phase 2 · 1 location(s) · Hospital Universitario Dr. Jose E. Gonzalez · NCT06886074Mosunetuzumab for CLL MRD Clearance
Phase 1/Phase 2 · 2 location(s) · Inhye Ahn · NCT07052695Clinical Validation and Benchmarking of Top Performing ctDNA Diagnostics - Stage III NSCLC
Phase N/A · 6 location(s) · University Medical Center Groningen · NCT06111807
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.